Stockscreener 앱 받기
54.14
1.42%
0.76
시간 외 거래:
55.10
0.96
+1.77%
전일 마감가:
$53.38
열려 있는:
$53.06
하루 거래량:
1.35M
Relative Volume:
0.60
시가총액:
$5.03B
수익:
$536.20M
순이익/손실:
$-45.64M
주가수익비율:
-101.23
EPS:
-0.5348
순현금흐름:
$-28.94M
1주 성능:
+15.83%
1개월 성능:
+27.12%
6개월 성능:
+59.75%
1년 성능:
+284.38%
1일 변동 폭
$53.06
$55.10
1주일 범위
$46.54
$55.10
52주 변동 폭
$13.88
$55.10
Travere Therapeutics Inc Stock (TVTX) Company Profile
명칭
Travere Therapeutics Inc
전화
888-969-7879
주소
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
54.14 | 5.00B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재개 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-21 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-12-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-20 | 개시 | Citigroup | Neutral |
| 2023-09-22 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 재개 | Evercore ISI | Outperform |
| 2023-07-21 | 개시 | JP Morgan | Overweight |
| 2023-06-07 | 재개 | Piper Sandler | Neutral |
| 2023-05-22 | 개시 | TD Cowen | Outperform |
| 2023-05-05 | 업그레이드 | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-21 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-12-14 | 개시 | Stifel | Hold |
| 2022-12-05 | 개시 | Wells Fargo | Overweight |
| 2022-09-21 | 개시 | Bryan Garnier | Sell |
| 2022-07-14 | 재개 | Canaccord Genuity | Buy |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-28 | 개시 | H.C. Wainwright | Buy |
| 2021-05-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
TVTX Maintained by Citigroup -- Price Target Raised to $70.00 - GuruFocus
Travere Therapeutics price target raised to $70 from $62 at Citi - TipRanks
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
TVTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now? - Insider Monkey
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
TVTX Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $65 - GuruFocus
Travere Therapeutics (TVTX) Gets a Buy from Wells Fargo - The Globe and Mail
Roy Baynes to sell 4,500 TVTX shares via option exercise (TVTX) - Stock Titan
TVTX (NASDAQ: TVTX) Form 144 reports 3,250-share sale - Stock Titan
Travere Stock At 20-Year High, Leads 21 Newcomers To Best Stock Lists Like Big Cap 20 - Investor's Business Daily
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Enidnews.com
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
Travere Therapeutics stock hits 52-week high at 48.7 USD By Investing.com - Investing.com Australia
Travere Therapeutics stock hits 52-week high at 48.7 USD - Investing.com
3 Stocks That May Be Priced Below Their Estimated Value In June 2026 - simplywall.st
Travere Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Discipline and Rules-Based Execution in TVTX Response - Stock Traders Daily
Travere therapeutics CCO sells $101,417 in stock for tax obligations - Investing.com
Travere therapeutics chief research officer Rote sells $121,433 in shares - Investing.com
Travere inks licensing deal worth up to $1.1B with China’s Everest Medicines - MSN
Travere buys BTK inhibitor for $1.1bn to treat kidney disease - BioXconomy
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion - ANTARA News
Travere Secures Global Rights to Civorebrutinib in $1.14 Billion Kidney Disease Partnership with Everest Medicines - BioPharma APAC
Travere Therapeutics (TVTX) Rises 2.72% as Stock Nears Key Resistance LevelAdaptive Moving Average - newsline.com
Travere Therapeutics, Inc. (TVTX) Stock: Phase 3 Extension Results Highlight Durable Proteinuria Reduction - parameter.io
Travere Therapeutics, Everest Medicines Partner to Advance Civorebrutinib - Contract Pharma
Travere Therapeutics CFO Cline sells $115,368 in company stock - Investing.com
Why is Travere Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Travere presents five-year FILSPARI data for rare kidney disease By Investing.com - Investing.com Australia
Travere Therapeutics (TVTX) Releases Promising Phase 3 Study Res - GuruFocus
Travere presents five-year FILSPARI data for rare kidney disease - Investing.com
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress - The AI Journal
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63 - Business Wire
Everest Medicines signs $1 B deal with Travere Therapeutics for rare kidney diseases treatment - BioSpectrum Asia
Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
Guggenheim Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
TVTX Maintained by Citigroup -- Price Target Raised to $62 - GuruFocus
TVTX Reiterated by Wedbush -- Price Target Maintained at $55 - GuruFocus
TVTX: Portfolio expands with civorebrutinib and FILSPARI growth; key clinical catalysts ahead - TradingView
Everest Meds strikes licensing pact with Travere - The Pharma Letter
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases - Macau Business
EVEREST MED (01952.HK) Signs Exclusive License and Collaboration Agreement with Travere Therapeutics, Inc. (TVTX.US), to Receive USD112.5M Upfront Payment - AASTOCKS.com
TVTX Maintained by HC Wainwright & Co. -- Price Target Raised to $67 - GuruFocus
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside - Yahoo Finance
Travere licenses kidney disease drug from Everest Medicines By Investing.com - Investing.com India
Travere Therapeutics Inc (TVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Travere Therapeutics Inc 주식 (TVTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Coughlin Timothy | Director |
Jun 12 '26 |
Sale |
50.07 |
10,000 |
500,747 |
56,250 |
| Baynes Roy D. | Director |
Jun 12 '26 |
Option Exercise |
21.38 |
4,500 |
96,210 |
46,000 |
| Baynes Roy D. | Director |
Jun 12 '26 |
Sale |
50.00 |
4,500 |
225,000 |
41,500 |
2.60%
0.94%
자본화:
|
볼륨(24시간):